vilazodone (Viibryd)
Jump to navigation
Jump to search
Indications
- major depression (FDA-approved Jan 2011)
Contraindications
- vilazodone & MAO inhibitors should not be used together or within 14 days of each other
Dosage
- start 10 mg QD with food
- after 7 days, increase to 20 mg QD
- after 14 days, increase to 40 mg QD, dose with food
- taper if discontinuing[2]
Tabs: 10, 20, 40 mg
Pharmacokinetics
- metabolized by CYP3A4
- inhibits CYP2C8
- protein-binding 96-99%
Adverse effects
- diarrhea (28%), nausea (23%), vomiting (5%)
- dizziness (9%)
- xerostomia (6%)
- xerophthalmia (5%)[2]
- insomnia
- may cause new or worsening cataracts[2]
- minimal or no sexual dysfunction
- minimal or no weight gain
- also see SSRI
- drug adverse effects of SSRIs
- drug adverse effects of antidepressants
- drug adverse effects of psychotropic agents
Drug interactions
- inhibitors of CYP3A4 may increase vilazodone levels
- vilazodone could potentially increase levels of drugs metabolized by CYP2C8[2]
- drug interaction(s) of oral anticoagulants with selective serotonin reuptake inhibitor (SSRI)
- drug interaction(s) of antidepressant in combination with GLP1-agonist
- drug interaction(s) of ondanstetron with SSRIs
- drug interaction(s) of dextromethorphan with SSRIs
- drug interaction(s) of trazodone with SSRIs
- drug interaction(s) of tramadol with SSRIs
- drug interaction(s) of triptans with SSRIs
- drug interaction(s) of anti-platelet agents with SSRIs
- drug interaction(s) of methylene blue with SSRIs
- drug interaction(s) of linezolid with SSRIs
- drug interaction(s) of statins with SSRIs
- drug interaction(s) of hypericum perforatum (Sr John's wort) with SSRI
- drug interaction(s) of tamoxifen with SSRI
- drug interaction(s) of benzodiazepines with antidepressants
- drug interaction(s) of antidepressants with benzodiazepines
- drug interaction(s) of NSAIDs with SSRIs
- drug interaction(s) of NSAIDs with antidepressants
- drug interaction(s) of antidepressant with opiates
- drug interaction(s) of coxib with SSRI
Laboratory
Mechanism of action
- combined selective serotonin reuptake inhibitor & serotonin 1A receptor partial agonist
More general terms
Additional terms
- serotonin [5HT]-1A receptor; 5-hydroxytryptamine receptor 1A; 5-HT-1A; 5-HT1A; serotonin receptor 1A; G-21 (HTR1A, ADRB2RL1, ADRBRL1)
- serotonin; 5-hydroxytryptamine
References
- ↑ FDA NEWS RELEASE, Jan. 21, 2011 FDA approves Viibryd to treat major depressive disorder http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm240642.htm
- ↑ 2.0 2.1 2.2 2.3 2.4 Prescriber's Letter 18(7): 2011 New Drug: Viibryd (Vilazodone) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270706&pb=PRL (subscription needed) http://www.prescribersletter.com